




RealRate

PHARMACEUTICAL 2018

Decoy Therapeutics Inc
Rank 169 of 332



Decoy Therapeutics Inc Rank 169 of 332

The relative strengths and weaknesses of Decoy Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Decoy Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 72% points. The greatest weakness of Decoy Therapeutics Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 59% points.

The company's Economic Capital Ratio, given in the ranking table, is 262%, being 10% points above the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	34,535
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,848
Liabilities, Non-Current	0
Other Assets	127
Other Compr. Net Income	0.37
Other Expenses	507
Other Liabilities	39
Other Net Income	292
Other Revenues	1,274
Property and Equipment	331
Research and Development	16,990
Selling, General and Administrative Expense	18,504

Output Variable	Value in 1000 USD
Assets	34,993
Liabilities	5,887
Expenses	36,000
Revenues	1,274
Stockholders Equity	29,106
Net Income	-34,434
Comprehensive Net Income	-34,433
BaseVar	39,223
ECR before LimitedLiability	142%
Economic Capital Ratio	262%